Sphingosine kinase type 1 inhibitors and uses thereof
US-10456370-B2 · Oct 29, 2019 · US
Sphingosine kinase Type 1 inhibitors and uses thereof
US11737992B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11737992-B2 |
| Application number | US-202117169662-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 8, 2021 |
| Priority date | Apr 29, 2008 |
| Publication date | Aug 29, 2023 |
| Grant date | Aug 29, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are inhibitors of sphingosine kinase Type I that are useful in the treatment of neuropathic pain.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating neuropathic pain in a patient, comprising: administering to a patient in need of treatment for neuropathic pain a compound having the formula 2. The method of claim 1 , wherein the administering step comprises administering to the patient. 3. The method of claim 2 , wherein the step of administering to the patient comprises administering HCl to the patient. 4. A method for treating neuropathic pain in a patient, comprising: administering to a patient in need of treatment for neuropathic pain a compound having the formula wherein R comprises a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. 5. The method of claim 4 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing. 6. The method of claim 5 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, or a hetero-aromatic ring. 7. The method of claim 6 , wherein R is a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, or a branched carbon chain comprising one or more heteroatoms. 8. The method of claim 7 , wherein R is a straight carbon chain or a branched carbon chain. 9. The method of claim 8 , wherein R is a straight carbon chain. 10. A method for treating neuropathic pain in a patient, consisting essentially of: administering to the patient.
Assignees
Inventors
Classifications
- A61K31/135Primary
having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)} · CPC title
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title
Antiasthmatics · CPC title
Centrally acting analgesics, e.g. opioids · CPC title
and containing six-membered aromatic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11737992B2 cover?
- Provided are inhibitors of sphingosine kinase Type I that are useful in the treatment of neuropathic pain.
- Who is the assignee on this patent?
- Enzo Therapeutics Inc, Univ Virginia Commonwealth
- What technology area does this patent fall under?
- Primary CPC classification A61K31/135. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).